Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Florbetaben · Neuraceq

Small molecule · Acts on amyloid beta neuritic plaques · developed by Lantheus Biosciences Ltd., A Lantheus Company

Approved FDA
LNTH Developer
2 Registered trials

What is Florbetaben?

Florbetaben is a radioactive diagnostic agent labeled with fluorine-18 for positron emission tomography (PET) of the brain. It estimates amyloid beta neuritic plaque density in adults with cognitive impairment. It is studied in Alzheimer's disease and in cardiac and light-chain amyloidosis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Neuraceq
Drug type
Small molecule
Targets
amyloid beta neuritic plaques (biomarker)
Mechanism
Acts on amyloid beta neuritic plaques
Therapy area
Neurology, Oncology
Developer
Lantheus Biosciences Ltd., A Lantheus Company (LNTH)
FDA status
Approved as Neuraceq, NDA204677 · FDA label
UNII
BMO5G62HGB

✅ FDA-approved uses

From the indications section of the FDA label (version of Jul 24, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05184088 Phase 3 Cardiac Amyloidosis Completed LNTH
NCT01020838 Phase 3 Alzheimer Disease Completed LNTH

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

AL AmyloidosisAlzheimer DiseaseATTR AmyloidosisCardiac Amyloidosis

More from Lantheus Biosciences Ltd., A Lantheus Company

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the LNTH page.

Follow LNTH, the company behind Florbetaben

See LNTH's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LNTH catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.